CHARLES SCHWAB INVESTMENT MANAGEMENT INC - AIMMUNE THERAPEUTICS INC ownership

AIMMUNE THERAPEUTICS INC's ticker is AIMT and the CUSIP is 00900T107. A total of 1 filers reported holding AIMMUNE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
CHARLES SCHWAB INVESTMENT MANAGEMENT INC ownership history of AIMMUNE THERAPEUTICS INC
ValueSharesWeighting
Q3 2020$10,420,000
+114.9%
302,463
+4.3%
0.01%
+150.0%
Q2 2020$4,848,000
+26.7%
290,119
+9.4%
0.00%0.0%
Q1 2020$3,826,000
-56.3%
265,289
+1.3%
0.00%
-60.0%
Q4 2019$8,764,000
+65.2%
261,818
+3.3%
0.01%
+66.7%
Q3 2019$5,306,000
+8.1%
253,354
+7.4%
0.00%0.0%
Q2 2019$4,910,000
-3.6%
235,801
+3.5%
0.00%0.0%
Q1 2019$5,095,000
-2.3%
227,923
+4.6%
0.00%
-25.0%
Q4 2018$5,213,000
-11.4%
217,904
+1.1%
0.00%0.0%
Q3 2018$5,881,000
+5.5%
215,577
+4.0%
0.00%0.0%
Q2 2018$5,574,000
-4.6%
207,255
+12.9%
0.00%
-20.0%
Q1 2018$5,844,000
+11.6%
183,577
+32.6%
0.01%
+25.0%
Q4 2017$5,237,000
+91.0%
138,448
+25.2%
0.00%
+100.0%
Q3 2017$2,742,000
+26.2%
110,580
+4.6%
0.00%0.0%
Q2 2017$2,173,000
+14.9%
105,689
+21.4%
0.00%0.0%
Q1 2017$1,892,000
+12.4%
87,057
+5.8%
0.00%0.0%
Q4 2016$1,683,000
+43.8%
82,269
+5.5%
0.00%
+100.0%
Q3 2016$1,170,000
+107.8%
77,957
+49.9%
0.00%0.0%
Q2 2016$563,000
+55.1%
51,994
+94.6%
0.00%
Q1 2016$363,000
-25.2%
26,716
+1.7%
0.00%
-100.0%
Q4 2015$485,000
+89.5%
26,257
+160.7%
0.00%
Q3 2015$256,00010,0720.00%
Other shareholders
AIMMUNE THERAPEUTICS INC shareholders Q4 2020
NameSharesValueWeighting ↓
Foresite Capital Management II, LLC 3,100,146$117,248,00040.96%
TLP GROUP LLC 1,050,000$39,711,00027.53%
Aisling Capital LLC 2,240,000$84,717,00016.74%
Foresite Capital Management III, LLC 764,824$28,926,0008.12%
AlpInvest Partners B.V. 51,498$1,948,0006.95%
Vivo Capital, LLC 643,626$24,342,0005.21%
GREAT POINT PARTNERS LLC 573,550$21,692,0003.70%
Eventide Asset Management 1,226,000$46,367,0002.42%
Palo Alto Investors LP 1,146,419$43,358,0001.87%
HAMILTON LANE ADVISORS LLC 78,846$2,982,0001.54%
View complete list of AIMMUNE THERAPEUTICS INC shareholders